Key Stats for IDEXX Stock
- Past-Week Performance: +0.6%
- 52-Week Range: $356.1 to $770
- Current Price: $577.3
What Happened?
Veterinary diagnostics leader IDEXX Laboratories (IDXX) delivered Q4 revenue of $1.09 billion, up 14% year-over-year, while its inVue Dx cell cytology analyzer, a point-of-care platform that automates slide preparation and delivers results in minutes, placed 6,400 units in 2025, doubling its original target of 4,500 and contributing 200 basis points to full-year revenue growth, even as the stock sits 25% below its 52-week high of $769.98 at $577.26.
Last February, IDEXX reported Q4 earnings per share of $3.08, beating consensus of $2.93, while guiding 2026 revenue to $4.63–$4.72 billion and EPS to $14.29–$14.80, both midpoints above analyst estimates of $4.66 billion and $14.50, though shares fell 6% to $628.70 as the company embedded a roughly 2% decline in U.S. same-store veterinary clinic visits into its base case.
CAG Diagnostics recurring revenue, the subscription-like consumables and testing revenue that represents approximately 79% of consolidated sales, grew 8% organically in 2025 and is guided to accelerate to 9% at the midpoint in 2026, a 100-basis-point step-up driven by inVue Dx pull-through, the controlled rollout of FNA capability for in-clinic tumor sampling, and Cancer Dx, a reference lab blood test for canine cancer priced at $15 when bundled into a wellness panel, which reached nearly 6,000 clinic customers by year-end 2025.
CEO Jay Mazelsky stated on the Q4 2025 earnings call that “early signs of aging pets with solid visit growth for canines 5-plus years old, more weighted to non-well, supported a second consecutive quarter of improving visits in this important segment,” pointing to the front end of a pandemic-era adoption wave that added 20 million-plus U.S. pets between 2020 and 2022 now entering the high-diagnostic-utilization 5-to-7-year age cohort.
Moreover, IDEXX’s incoming CEO Michael Erickson, a 15-year company veteran set to take the role after the May 12 annual meeting, inherits a platform with $1.1 billion in projected Cancer Dx TAM, a commitment to detect 50%-plus of common canine cancers by end of 2028, and a capital return program that repurchased $1.2 billion in shares in 2025, with a 2026 target of 1%–2% further diluted share reduction, positioning the company to compound EPS at 15%-plus annually against a $45 billion-plus veterinary services addressable market.
Wall Street’s Take on IDXX Stock
The 6% post-earnings selloff that pushed IDEXX to $628.70 on February 3 and now $577.26 misreads the guidance: the company embedded a 2% U.S. clinic visit decline into its 2026 base case yet still guided EPS to $14.29–$14.80, implying 10%–14% comparable growth off a $13.08 base.
Revenue is estimated to grow 8.8% to $4.68 billion in 2026, supported by 8%–10% organic CAG Diagnostics recurring revenue growth, the consumables and testing stream that represents 79% of sales and expands independently of visit volumes through higher diagnostic frequency per visit.
Nine of 13 covering analysts rate IDEXX a buy or outperform, with a mean price target of $750.23, implying 30.0% upside from $577.26, as Wall Street anticipates the aging pandemic pet cohort and inVue Dx installed base pull-through to accelerate recurring revenue beyond the current 8% organic floor.
The analyst price target range runs from $470.00 to $823.00: the low anchors to a prolonged wellness visit contraction that pressures consumable volumes, while the high captures full execution on the Cancer Dx panel expansion to 50%-plus of common canine cancers by end of 2028 and continued double-digit international CAG growth.
What Does the Valuation Model Say?
The TIKR mid-case model prices IDEXX at $946.36, implying a 10.9% IRR over 4.8 years, driven by an 8.8% revenue CAGR, EBITDA margin expansion from 35.0% in 2025 to 38.5% by 2030, and EPS compounding from $13.08 to $23.28 across that period, all anchored to inVue Dx pull-through, Cancer Dx panel additions, and the $1.1 billion long-term Cancer Dx TAM now in active commercialization.
The market is treating IDEXX as a vet visit stock, but recurring diagnostic revenue grew 8% organically in 2025 against a 1.9% full-year visit decline.
The TIKR mid-case target of $946.36 rests on sustained 8%-plus recurring revenue growth, a rate IDEXX has already demonstrated even with visits negative, backed by a 12% installed base expansion and over 6,000 inVue Dx units in the field.
Also, Mazelsky confirmed on the Q4 earnings call that diagnostic frequency per visit is expanding at 2x historical rates, meaning the per-visit revenue yield is rising independently of whether more pets walk through the door.
The single assumption that breaks the model is a sustained deterioration in non-wellness visits, which currently represent 60% of clinic traffic but 70%–75% of diagnostics revenue, making any macro-driven shift in sick-patient visit behavior a direct hit to recurring revenue growth.
The Q1 2026 earnings report is the first proof point: CAG Diagnostics recurring revenue growth guidance of 8.5%–10.5% organic sets a clear trackable range, and any print at the high end resets the visit-pressure narrative.
Should You Invest in IDEXX Laboratories, Inc.?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up IDEXX stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track IDEXX Laboratories, Inc. alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze IDEXX stock on TIKR for Free →
